Insomnia, depression, and medication effects on mild cognitive impairment to dementia progression: a nationwide trinetx cohort study

Active Grant Awarded

Award ID
R21AG104024
Recipient
Awarding agency
Obligated
$423,500

Award facts

Assistance listing
93.866 Aging Research
Completion date 10% complete
Place of performance
St. Louis, MO 63103, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Saint Louis University $423,500 obligated on September 9, 2026, under Assistance Listing 93.866, Aging Research, for Grant R21AG104024, "Insomnia, Depression, and Medication Effects on Mild Cognitive Impairment to Dementia Progression: A Nationwide TriNetX Cohort Study." The R21 project will examine the combined effect of insomnia and major depressive disorder on progression from mild cognitive impairment to Alzheimer's disease and related dementias, assess how real-world prescribing patterns and their changes over time influence that progression, and test whether these associations vary by age, race, and sex. Progression will be assessed using longitudinal electronic health records linked to matched claims for approximately 7.8 million patients. Work is performed in St. Louis, Missouri 63103, and the period of performance runs through August 31, 2028.

Description

Abstract
Annually, up to 15% of patients with mild cognitive impairment (MCI) progress to alzheimer's disease and related dementias (ADRD)-debilitating and incurable conditions with limited treatments-and, cumulatively, as many as 80% progress within six years. The economic impact is substantial, with total social costs projected to be $707 billion in 2024 and rising as the population ages. Identifying modifiable risk factors is crucial, as delaying ADRD onset by five years could prevent ~1 million cases in the next decade. Insomnia and major depressive disorder (MDD) are key modifiable risk factors independently linked to ADRD. Yet, two major gaps remain: 1) few studies have evaluated their combined effect on MCI-to-ADRD progression, despite their frequent CO- occurrence (59% of MDD patients have insomnia, which increases depression risk by 2.6 times); and 2) the influence of contemporary prescribing patterns for insomnia and MDD on progression remains unclear. While antidepressants and sedative-hypnotics may relieve symptoms, medications such as benzodiazepines and some non-benzodiazepine hypnotics have been associated associated with worsened cognition. MCI remains markedly underdiagnosed-only ~8% of expected cases are documented-leaving more than 90% undetected. Nevertheless, a documented MCI diagnosis provides a pragmatic "early-warning" stage for surveillance and prevention. This R21 proposal will: 1) examine the combined effect of insomnia and MDD on progression to ADRD among patients with MCI; 2) assess how real-world prescribing patterns, and their changes over time, influence MCI-to-ADRD progression; and 3) test whether associations vary by age, race, and SEX. We will assess progression using longitudinal electronic health records linked to matched claims for ~7.8 million patients across 35 health care organizations, with 2011-2013 eligibility and 11-14 years of follow-up. The proposed research will generate preliminary evidence on the safety of pharmaceutical treatments, inform treatment algorithms, and lay the foundation for future interventions that enable clinicians and patients to engage in shared decision-making.

Quick answers

Who received award R21AG104024?

R21AG104024 was awarded to Saint Louis University by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R21AG104024 worth?

$423,500 has been obligated on R21AG104024.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award